1,1-difluoro-3,3-dimethyl-butan-2-one | 66032-79-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,1-difluoro-3,3-dimethyl-butan-2-one
• 英文别名: Difluormethyl-t-butylketon；1,1-Difluoro-3,3-dimethylbutan-2-one
• CAS: 66032-79-9
• 化学式: C₆H₁₀F₂O
• 分子量: 136.142
• InChiKey: LLVUXSVKKUDOLU-UHFFFAOYSA-N

物化性质

• 沸点：
  116.4±25.0 °C(Predicted)
• 密度：
  1.000±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-diazo-3,3-dimethyl-2-butanone 在 三氟甲基次氟酸酯 、 一氟三氯甲烷 作用下， 生成 1,1-difluoro-3,3-dimethyl-butan-2-one
  参考文献：
  名称：

  Leroy,J.; Wakselman,C., Journal of the Chemical Society. Perkin transactions I, 1978, p. 1224 - 1227

  摘要：

  DOI：

文献信息

• HEPATITIS B ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20190177320A1

  公开（公告）日：2019-06-13

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）的化合物或其药学上可接受的盐：这些化合物抑制乙型肝炎病毒（HBV）编码的蛋白质或干扰HBV生命周期的功能，同时也作为抗病毒剂使用。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给受试者投予包含本发明化合物的药物组合物来治疗HBV感染的方法。
• SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS
  申请人：OSCOTEC, INC.

  公开号：US20130274242A1

  公开（公告）日：2013-10-17

  Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I).

  本文披露了化学式(I)的化合物及其抑制酶，包括脾酪氨酸激酶的方法。同时还披露了通过向受试者施用化学式(I)化合物的治疗有效剂量来治疗酶介导的疾病或状况的方法。
• PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
  申请人：Wrobleski Stephen T.

  公开号：US20140011800A1

  公开（公告）日：2014-01-09

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

  本发明提供了I型化合物及其药学上可接受的盐。式I化合物抑制JAK3的酪氨酸激酶活性，因此可用于治疗炎症和自身免疫性疾病。
• Imidazole derivative used as antiviral agent and use thereof in preparation of medicament
  申请人：Shandong Danhong Pharmaceutical Co., Ltd.

  公开号：US10030029B2

  公开（公告）日：2018-07-24

  Disclosed are an antiviral compound and a use thereof in the preparation of a medicament for the treatment of virus infections. Specifically, the present invention relates an imidazole derivative for treating respiratory syncytial virus infection.

  本发明公开了一种抗病毒化合物及其在制备治疗病毒感染的药物中的用途。具体而言，本发明涉及一种用于治疗呼吸道合胞病毒感染的咪唑衍生物。
• Hepatitis B antiviral agents
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US10189846B2

  公开（公告）日：2019-01-29

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物或其药学上可接受的盐类： 其可抑制乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒 HBV 生命周期的功能，还可用作抗病毒剂。本发明进一步涉及包含上述化合物的药物组合物，用于给受 HBV 感染的患者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 HBV 感染的方法。